Other CCR5-neutralising molecules, including the non-peptide antagonist TAK-779 and mouse anti-CCR5, have also shown promising results in pre-clinical models of pancreatic cancer and melanoma, by restricting the migration of MDSCs and Treg cells into the TME [111,112]. This evidence concerns the gene CCR5 and melanoma.